Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hemophilus parasuis disease, swine streptococcosis bivalent inactivated vaccine and preparation method thereof

A technology of haemophilus suis disease and double inactivated vaccine, which is applied in the direction of antibacterial drugs, pharmaceutical formulas, bacterial antigen components, etc. Questions about vaccine antigens

Active Publication Date: 2013-06-19
PU LIKE BIO ENG
View PDF12 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The adjuvant of the vaccine is white oil, and the side effects of the adjuvant vaccine are relatively large, which will cause inflammation or swelling at the injection site; in addition, according to research data, the use of mineral oil adjuvants will stimulate and improve the porcine ring and so on to a certain extent. The incidence of pig diseases
Moreover, in the preparation process of the vaccine, the obtained antigen has no judgment and relevant inspection of the inactivation effect after inactivation, and it is impossible to know whether the antigen inactivation is complete, and the obtained antigen cannot be used as an antigen for vaccine production.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hemophilus parasuis disease, swine streptococcosis bivalent inactivated vaccine and preparation method thereof
  • Hemophilus parasuis disease, swine streptococcosis bivalent inactivated vaccine and preparation method thereof
  • Hemophilus parasuis disease, swine streptococcosis bivalent inactivated vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Embodiment 1: Preparation of Haemophilus parasuis, Streptococcus suis dual inactivated vaccine (JS strain+ZJ strain+SC strain)

[0059] 1. Preparation of strains for production

[0060] Haemophilus parasuis serotype 4 JS strain, type 5 ZJ strain and Streptococcus suis type 2 SC strain were propagated by primary seed and secondary seed propagation to obtain Haemophilus parasuis serotype 4 JS strain and type 5 ZJ strain strains and Streptococcus suis type 2 SC strains for production.

[0061] (1) Primary seed propagation

[0062] Primary seed propagation was carried out on Haemophilus parasuis serotype 4 JS strain, type 5 ZJ strain and Streptococcus suis type 2 SC strain. Streak and inoculate the freeze-dried strains of Haemophilus parasuis serotype 4 JS strain and type 5 ZJ strain on the TSA / NAD plate, culture them at 37°C for 18 hours, select colonies that meet the requirements, and inoculate them on TSB / NAD liquid medium, cultivated at 37°C for 12 hours, as the pri...

Embodiment 2

[0097] Embodiment 2: safety research

[0098] (1) Safety test of the vaccine on Balb / C mice

[0099] The vaccine prepared in Example 1 was used to inoculate 10 Balb / C mice of 18 to 22 g each, each subcutaneously injected with 0.4 ml, and observed for 14 days. There was no local reaction and all were healthy and alive, as shown in Table 2.

[0100] Table 2 vaccine is to Balb / C mouse safety test result

[0101]

[0102] (2) Safety test of vaccine on piglets

[0103] The vaccine prepared in Example 1 was injected intramuscularly into 5 30-day-old healthy susceptible pigs, each with 4 mL, and there was no local reaction within 14 days and all were healthy and alive. The test results are shown in Table 3.

[0104] Table 3 vaccine is to the safety test result of piglet

[0105]

[0106]

[0107] It can be seen from the safety test results that Haemophilus parasuis, Streptococcus suis double aluminum hydroxide gel adjuvant inactivated vaccine (JS strain + ZJ strain + SC ...

Embodiment 3

[0108] Embodiment 3: Efficacy test (tested in our company's experimental animal room)

[0109] (1) Efficacy test in Balb / C mice

[0110] Balb / C mice weighing 18-22 g were subcutaneously inoculated with 0.1 mL of double inactivated vaccine, and divided into 3 groups 21-28 days after immunization, together with 10 mice in each group of the control group, and treated with Haemophilus parasuis serum type 4 JS Intraperitoneally inject 1ml of the strain (the bacteria content is 4.0×10 9 CFU), type 5 ZJ strains were intraperitoneally injected with 1ml (the bacterial content was 2.5×10 9 CFU); and subcutaneous injection of 1ml of Streptococcus suis type 2 SC strain (the bacterial content is 1.0×10 2 CFU), another 10 were set as blank control, observed for 14 days, and the test results are shown in Table 4.

[0111] Table 4Balb / C mouse potency test result

[0112]

[0113] (2) Piglet efficacy test

[0114] Take the prepared vaccine, use 15 healthy susceptible pigs aged 28-35 da...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a hemophilus parasuis disease, a swine streptococcosis bivalent inactivated vaccine and a preparation method thereof. The vaccine is prepared by adopting a hemophilus parasuis serotype 4 JS strain, a hemophilus parasuis serotype 5 ZJ strain and a streptococcus suis type 2 SC strain as antigens, and adopting a veterinarily acceptable adjuvant, concurrently provides immunoprophylaxis for hemophilus parasuis diseases caused by hemophilus parasuis, swine streptococcosis caused by streptococcus suis, and mixed infection of the hemophilus parasuis disease and the swine streptococcosis, has effects of low side effect, no endotoxin, no impurity protein in serum, good immunization safety, multi-prevention effect with one needle in the clinic, and cost reducing, and can meet different requirements of different users.

Description

technical field [0001] The invention relates to the technical field of animal biopharmaceuticals, in particular to a dual inactivated vaccine of Haemophilus parasuis and Streptococcus suis and a preparation method thereof. Background technique [0002] Haemophilus parasuis and Streptococcus suis are the two most important bacterial infectious diseases in pig herds in my country. Haemophilus parasuis disease is multiple serositis and arthritis of pigs caused by Haemophilus parasuis (Hps), which is also known as Glsser's Disease. Haemophilus parasuis can affect young pigs from 2 weeks to 4 months, mainly in post-weaning and nursery stages, usually seen in pigs aged 5 to 8 weeks, the incidence rate can reach 40%, and the mortality rate can reach 50% %. The main clinical symptoms were cough, dyspnea, emaciation, lameness, and rough coat; the main necropsy lesions were fibrinous pleurisy, pericarditis, peritonitis, arthritis, and meningitis. In addition, Haemophilus parasuis c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/116A61P31/04A61K39/09A61K39/102
Inventor 张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com